Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

BACKGROUND: The oral proteasome inhibitor ixazomib is under phase 3 clinical investigation in multiple myeloma (MM) in combination with lenalidomide–dexamethasone. This study was conducted to investigate the pharmacokinetic and safety profiles of ixazomib, administered with lenalidomide–dexamethason...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Gupta, Neeraj, Goh, Yeow Tee, Min, Chang-Ki, Lee, Jae Hoon, Kim, Kihyun, Wong, Raymond S. M., Chim, Chor Sang, Hanley, Michael J., Yang, Huyuan, Venkatakrishnan, Karthik, Hui, Ai-Min, Esseltine, Dixie-Lee, Chng, Wee Joo
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4559079/
https://ncbi.nlm.nih.gov/pubmed/26337806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0198-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados